|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 27398 |
FusionGeneSummary for PKN2_TXK |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: PKN2_TXK | Fusion gene ID: 27398 | Hgene | Tgene | Gene symbol | PKN2 | TXK | Gene ID | 5586 | 7294 |
| Gene name | protein kinase N2 | TXK tyrosine kinase | |
| Synonyms | PAK2|PRK2|PRKCL2|PRO2042|Pak-2|STK7 | BTKL|PSCTK5|PTK4|RLK|TKL | |
| Cytomap | 1p22.2 | 4p12 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase N2PKN gammacardiolipin-activated protein kinase Pak2protein kinase C-like 2protein-kinase C-related kinase 2 | tyrosine-protein kinase TXKPTK4 protein tyrosine kinase 4protein-tyrosine kinase 4resting lymphocyte kinase | |
| Modification date | 20180523 | 20180523 | |
| UniProtAcc | Q16513 | P42681 | |
| Ensembl transtripts involved in fusion gene | ENST00000316005, ENST00000370521, ENST00000370505, ENST00000370513, ENST00000544045, ENST00000495119, | ENST00000264316, ENST00000510457, ENST00000507351, | |
| Fusion gene scores | * DoF score | 4 X 4 X 2=32 | 1 X 1 X 1=1 |
| # samples | 5 | 2 | |
| ** MAII score | log2(5/32*10)=0.643856189774725 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(2/1*10)=4.32192809488736 | |
| Context | PubMed: PKN2 [Title/Abstract] AND TXK [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | PKN2 | GO:0006468 | protein phosphorylation | 17332740 |
| Hgene | PKN2 | GO:0010631 | epithelial cell migration | 21754995 |
| Tgene | TXK | GO:0006357 | regulation of transcription by RNA polymerase II | 11859127 |
| Tgene | TXK | GO:0006468 | protein phosphorylation | 17177976 |
| Tgene | TXK | GO:0032729 | positive regulation of interferon-gamma production | 10523612|11859127 |
| Tgene | TXK | GO:0045944 | positive regulation of transcription by RNA polymerase II | 11859127 |
| Tgene | TXK | GO:0046777 | protein autophosphorylation | 12081135|17177976 |
| Tgene | TXK | GO:0060335 | positive regulation of interferon-gamma-mediated signaling pathway | 11859127 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChiTaRS3.1 | H87820 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - | ||
| ChiTaRS3.1 | BX092188 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| intron-intron | ENST00000316005 | ENST00000264316 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000316005 | ENST00000510457 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000316005 | ENST00000507351 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370521 | ENST00000264316 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370521 | ENST00000510457 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370521 | ENST00000507351 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370505 | ENST00000264316 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370505 | ENST00000510457 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370505 | ENST00000507351 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370513 | ENST00000264316 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370513 | ENST00000510457 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000370513 | ENST00000507351 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000544045 | ENST00000264316 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000544045 | ENST00000510457 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000544045 | ENST00000507351 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000495119 | ENST00000264316 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000495119 | ENST00000510457 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
| intron-intron | ENST00000495119 | ENST00000507351 | PKN2 | chr1 | 89281547 | + | TXK | chr4 | 48134719 | - |
Top |
FusionProtFeatures for PKN2_TXK |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| PKN2 | TXK |
| PKC-related serine/threonine-protein kinase and Rho/Raceffector protein that participates in specific signal transductionresponses in the cell. Plays a role in the regulation of cellcycle progression, actin cytoskeleton assembly, cell migration,cell adhesion, tumor cell invasion and transcription activationsignaling processes. Phosphorylates CTTN in hyaluronan-inducedastrocytes and hence decreases CTTN ability to associate withfilamentous actin. Phosphorylates HDAC5, therefore lead to impairHDAC5 import. Direct RhoA target required for the regulation ofthe maturation of primordial junctions into apical junctionformation in bronchial epithelial cells. Required for G2/M phasesof the cell cycle progression and abscission during cytokinesis ina ECT2-dependent manner. Stimulates FYN kinase activity that isrequired for establishment of skin cell-cell adhesion duringkeratinocytes differentiation. Regulates epithelial bladder cellsspeed and direction of movement during cell migration and tumorcell invasion. Inhibits Akt pro-survival-induced kinase activity.Mediates Rho protein-induced transcriptional activation via the c-fos serum response factor (SRF). Phosphorylates HCV NS5B leadingto stimulation of HCV RNA replication. Involved in the negativeregulation of ciliogenesis (PubMed:27104747).{ECO:0000269|PubMed:10226025, ECO:0000269|PubMed:10926925,ECO:0000269|PubMed:11777936, ECO:0000269|PubMed:11781095,ECO:0000269|PubMed:15364941, ECO:0000269|PubMed:17332740,ECO:0000269|PubMed:20188095, ECO:0000269|PubMed:20974804,ECO:0000269|PubMed:21754995, ECO:0000269|PubMed:27104747,ECO:0000269|PubMed:9121475}. | Non-receptor tyrosine kinase that plays a redundant rolewith ITK in regulation of the adaptive immune response. Regulatesthe development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells(APC) activate T-cell receptor (TCR), a series of phosphorylationlead to the recruitment of TXK to the cell membrane, where it isphosphorylated at Tyr-420. Phosphorylation leads to TXK fullactivation. Contributes also to signaling from many receptors andparticipates in multiple downstream pathways, including regulationof the actin cytoskeleton. Like ITK, can phosphorylate PLCG1,leading to its localization in lipid rafts and activation,followed by subsequent cleavage of its substrates. In turn, theendoplasmic reticulum releases calcium in the cytoplasm and thenuclear activator of activated T-cells (NFAT) translocates intothe nucleus to perform its transcriptional duty. With PARP1 andEEF1A1, TXK forms a complex that acts as a T-helper 1 (Th1) cell-specific transcription factor and binds the promoter of IFNG todirectly regulate its transcription, and is thus involvedimportantly in Th1 cytokine production. Phosphorylates both PARP1and EEF1A1. Phosphorylates also key sites in LCP2 leading to theup-regulation of Th1 preferred cytokine IL-2. Phosphorylates 'Tyr-201' of CTLA4 which leads to the association of PI-3 kinase withthe CTLA4 receptor. {ECO:0000269|PubMed:10523612,ECO:0000269|PubMed:11564877, ECO:0000269|PubMed:11859127,ECO:0000269|PubMed:17177976, ECO:0000269|PubMed:9813138}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for PKN2_TXK |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for PKN2_TXK |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for PKN2_TXK |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for PKN2_TXK |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|